spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  alendronate 

 HSMN NewsFeed - 29 May 2023
Abiogen Pharma Completes the Acquisition of Effrx
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Dec 2019
European Commission Approves EVENITY(R) (romosozumab) For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Oct 2019
EVENITY(R) (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jun 2019
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Jan 2019
EVENITY(TM) (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Jul 2018
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Jul 2017
Amgen And UCB Provide Update On Regulatory Status Of EVENITY(TM) (romosozumab) In The US
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 May 2017
Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY(TM) (Romosozumab) In Postmenopausal Women With Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 28 Apr 2017
FDA Approves Radius Health’s TYMLOS(TM) (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Dec 2016
Grünenthal Receives Breakthrough Therapy Designation From U.S. FDA for Neridronic Acid for the Treatment of CRPS
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Feb 2013
Amgen Outlines Long-Term Strategy
Biopharmaceuticals
 HSMN NewsFeed - 14 Mar 2012
FDA Approves BINOSTO(TM), First and Only Effervescent Osteoporosis Treatment in a Buffered Solution
Biopharmaceuticals Drug Delivery Licensing FDA
 HSMN NewsFeed - 1 Jun 2010
FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Dec 2009
Merck Appoints Dr. Michael Rosenblatt As Executive Vice President & Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Dec 2008
First Head-To-Head Study Shows That Protelos(R) (Strontium Ranelate) Builds Better Bone Than Bisphosphonate
Biopharmaceuticals
 HSMN NewsFeed - 15 Sep 2008
Denosumab Osteoporosis Trial Finds Patients Transitioned from Alendronate (Fosamax(R)) to Denosumab Achieved Significantly Greater Gains in Bone Mineral Density versus Those Continuing on Alendronate
Biopharmaceuticals
 HSMN NewsFeed - 12 Sep 2008
Sun Pharma Gets USFDA Approval for Generic Fosamax (R) Tablets
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 28 May 2008
Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial versus Weekly Alendronate (FOSAMAX(R))
Biopharmaceuticals
 HSMN NewsFeed - 19 May 2008
Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition Study
Biopharmaceuticals
 HSMN NewsFeed - 25 Feb 2008
Teva Announces Two Court Decisions to Revoke MSD's European Patent on Generic Fosamax(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 6 Feb 2008
Barr Launches Generic Fosamax(R) Tablets, 70 mg
Biopharmaceuticals FDA Generics
 HSMN NewsFeed - 6 Feb 2008
Teva Announces Approval of Generic Fosamax(R) Tablets, 5 mg, 10 mg, 35 mg, 40 mg and 70 mg
Biopharmaceuticals FDA Generics
 HSMN NewsFeed - 24 Jan 2008
Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R))
Biopharmaceuticals
 HSMN NewsFeed - 14 Nov 2007
FORTEO(R) Increased Spine Bone Mineral Density in Patients with Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 1 Nov 2007
Bentley Announces Its First Product Approval in France
Biopharmaceuticals Generics Regulatory
 HSMN NewsFeed - 29 Oct 2007
Bentley Announces Product Approvals in Spain and Ireland
Biopharmaceuticals Generics Regulatory
 HSMN NewsFeed - 19 Sep 2007
New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 16 Jul 2007
Bentley Announces Product Approvals for Generic Pharmaceuticals
Biopharmaceuticals Generics Regulatory
 HSMN NewsFeed - 15 May 2007
Array BioPharma Appoints John Yates, MB ChB, MD, to Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jan 2007
Agreement between Ipsen and MSD for the Co-Marketing in France of Adrovance(TM) for the Treatment of Postmenopausal Osteoporosis
Biopharmaceuticals Licensing
 HSMN NewsFeed - 19 Sep 2006
Higher Persistency Rates Seen with FOSAMAX(R) Once Weekly Therapies Compared to Other Weekly and Monthly Oral Bisphosphonates, According to Two New Outcomes Studies
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2006
Women More Likely to Stay on Once-Monthly Boniva(R) Versus Once-Weekly Osteoporosis Medicines
Biopharmaceuticals
 HSMN NewsFeed - 16 Sep 2006
Once-Yearly Reclast(R)* Demonstrates Highly Significant Fracture Risk Reductions in the Treatment of Postmenopausal Osteoporosis, New Study Shows
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 14

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 14 additional stories matching:
alendronate
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.